Dose-Expansion Portion of Phase 1 Study of E7090 in Patients with CCA

2020 Year in Review: Cholangiocarcinoma — December 19, 2020

Interim analysis of the part 2 dose-expansion portion of an ongoing 2-part phase 1 Japanese study shows that the FGFR1 tyrosine kinase inhibitor E7090 was active with a manageable safety profile in CCA patients with FGFR2 gene fusion.

Fibroblast growth factor receptor (FGFR) genetic alterations, including gene fusion, mutation, and amplification, have been implicated in several cancers, including cholangiocarcinoma (CCA). E7090 is a selective tyrosine kinase inhibitor (TKI) directed against FGFR1 that has shown promising preclinical activity in models harboring genetic alterations.1 An ongoing 2-part, first-in-human, phase 1 study is being conducted in Japan to evaluate the tolerability and safety of E7090 in patients with advanced solid tumors. In the part 1 portion of this study, which evaluated the toxicity, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of E7090, no dose-limiting toxicities were identified and the recommended phase 2 dose was determined to be 140 mg daily. Interim analysis of the part 2 dose-expansion portion of this study in patients who harbored FGFR2 gene alterations were reported at the American Society of Clinical Oncology (ASCO) 2020 Gastrointestinal Cancers Symposium.

In the part 2 dose-expansion portion of the study, eligibility criteria included patients with CCA harboring FGFR2 gene fusion and gastric cancer harboring FGFR2 gene amplification or FGFR2 protein high expression, and failure of standard therapies or for whom no appropriate treatment is available. Eligible patients received E7090 until disease progression or unacceptable toxicity.

At the time of data cutoff (July 31, 2019), 16 patients were enrolled in part 2, including 6 patients in the CCA cohort and 10 patients in the gastric cancer cohort. In the CCA study population, median age was 53.7 years, 16.7% were female, and 50% of patients had Eastern Cooperative Oncology Group (ECOG) performance status of 1. Five (83%) patients had received ≥2 previous treatments, and 3 (50%) had undergone surgery.

In terms of tumor response per investigator assessment, 5 (83%) patients achieved partial response as the best overall response; 1 patient achieved stable disease for a disease control rate of 100%. In Kaplan-Meier plots, median progression-free survival (PFS) was 8.26 months, and median overall survival (OS) was not estimable. Two patients remain on treatment.

In the total population (CCA and gastric cancer cohorts), grade 3/4 treatment-emergent adverse events (AEs) occurred in 11 (69%) patients and grade 3/4 treatment-related AEs in 12.5%. Treatment-emergent serious AEs occurred in 5 (31%) patients; none of which were treatment-related. Dose reductions due to treatment-emergent AEs occurred in 5 (31%) patients. The most common treatment-related AEs (≥30%) included hyperphosphatemia (100%), palmar-plantar erythrodysesthesia syndrome (56%), paronychia (50%), dysgeusia (31%), stomatitis (31%), diarrhea (25%), increased aspartate aminotransferase (12.5%), and blood creatinine increased (19%).

Based on the results of the part 2 dose-expansion portion of the phase 1 study, the investigators concluded that E7090 was associated with promising clinical activity and a manageable safety profile in CCA patients with FGFR2 gene fusion; for these reasons, a phase 2 study has been initiated in patients with CCA harboring FGFR2 gene fusion.

Source: Morizane C, et al. J Clin Oncol. 2020;38(4_suppl). Abstract 538.

Reference

  1. Miyano SW, Yamamoto Y, Kodama K, et al. E7090, a novel selective inhibitor of fibroblast growth factor receptors, displays potent antitumor activity and prolongs survival in preclinical models. Mol Cancer Ther. 2016;15:2630-2639.

Related Items

KEYNOTE-966: Pembrolizumab Combined With GemCis Versus GemCis Alone in Patients With BTC
2023 Year in Review: Cholangiocarcinoma
In the KEYNOTE-966 study, pembrolizumab was added to gemcitabine/cisplatin to assess outcomes in patients with advanced biliary tract cancer.
Post-hoc Analysis of the ABC-01, -02, and -03 Trials in Patients With Advanced eCCA
2023 Year in Review: Cholangiocarcinoma
This post-hoc analysis of the ABC-01, -02, and -03 clinical trials provides reference survival data for patients with advanced extrahepatic cholangiocarcinoma treated with first-line gemcitabine/cisplatin chemotherapy.
Efficacy and Safety of Tinengotinib in Patients With Advanced Refractory/Relapsed CCA Who Previously Received an FGFR Inhibitor
2023 Year in Review: Cholangiocarcinoma
Investigators pooled data from 3 trials to evaluate tinengotinib in patients with advanced, refractory/relapsed cholangiocarcinoma who previously received an FGFR inhibitor.
KLF5 Inhibition Reduces Tumor Growth and Sensitizes to Chemotherapy-Induced Cell Death in Experimental Models of CCA
2023 Year in Review: Cholangiocarcinoma
Researchers evaluated KLF5 expression and its inhibition in cholangiocarcinoma using clustered regularly interspaced short palindromic repeats technology.
Phase 2 Trial of SHR-1316 Plus IBI310 in Patients With Advanced iCCA After Inadequate Response to First-Line Therapy
2023 Year in Review: Cholangiocarcinoma
In this ongoing phase 2 study, the efficacy of SHR-1316 plus IBI310 is being evaluated in patients with advanced intrahepatic cholangiocarcinoma after inadequate response to first-line therapy.
Examination of Patients With CCA Treated With Novel Targeted Therapies After Extended Molecular Profiling on Liquid Biopsies
2023 Year in Review: Cholangiocarcinoma
Dr Mahmood presented results from the largest multi-institutional review of efficacy outcomes following targeted agents in patients with cholangiocarcinoma.
Phase 2 Component of the BEER-BTC Study: Comparing Bevacizumab Plus Erlotinib Maintenance Versus Observation in Patients With Advanced BTC
2023 Year in Review: Cholangiocarcinoma
In the phase 2 component of the phase 2/3 BEER-BTC study, bevacizumab plus erlotinib improved outcomes in patients with advanced biliary tract cancers.
The DEBATE Trial: Neoadjuvant Durvalumab Plus GemCis Versus GemCis Alone for Patients With Localized BTC
2023 Year in Review: Cholangiocarcinoma
Researchers investigated the efficacy and safety of neoadjuvant durvalumab plus gemcitabine/cisplatin (GemCis) versus GemCis alone in patients with biliary tract cancer.
The Phase 2 ADJUBIL Study of Durvalumab Plus Tremelimumab With or Without Capecitabine in BTC
2023 Year in Review: Cholangiocarcinoma
In the ongoing phase 2 ADJUBIL study, the clinical activity of immunotherapies durvalumab and tremelimumab with or without capecitabine is being assessed in patients with resectable biliary tract cancer in the adjuvant setting.
Tucatinib and Trastuzumab in Patients With Previously Treated HER2-Positive Metastatic BTC: The SGNTUC-019 Study
2023 Year in Review: Cholangiocarcinoma
This phase 2 basket study investigated the combination of tucatinib and trastuzumab as second-line treatment for patients with HER2-positive biliary tract cancer.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: